

PRESS RELEASE

13 October 2023 15:05:00 CEST

Senzime secures contract with top-10 ranked, US East Coast-based university hospital system

Senzime, an industry leader in algorithm-based patient monitoring solutions, today announces a supply contract with a top-10 ranked US East Coast-based university hospital system. The contract is the result of a comprehensive clinical and competitive product evaluation and includes TetraGraph monitoring systems for use in pediatric and adult care.

“This is another major milestone for Senzime in the US market. We continue to demonstrate that we are the trusted vendor of choice for leading US hospital systems. Contracts like this are the result of the dedication and expertise of our clinical and commercial teams, as well as Senzime’s unique position as the sole vendor that can offer a comprehensive portfolio of guideline-compliant neuromuscular monitoring solutions for adults, pediatrics, and patients with sensitive and fragile skin,” comments Philip Siberg, CEO of Senzime.

The TetraGraph is the first portable electromyography (EMG)-based neuromuscular monitor on the market that is clinically validated and that meets the new clinical guidelines published by the ASA (American Society of Anesthesiologists) and ESAIC (European Society of Anaesthesiology and Intensive Care). Since market introduction in 2019, the TetraGraph has been installed at hundreds of leading hospitals across the globe.

The TetraGraph system is used during surgery to accurately monitor the patient’s level of neuromuscular block. This helps anesthesiologists secure the right dose of neuromuscular blocking drugs and their antagonists, as well as indicate when it is safe to allow patients to breathe on their own.

The contract has potential to reach 20,000 patients per year when monitors are in full use. Initial deliveries commence immediately.

For further information, please contact:

Philip Siberg, CEO of Senzime AB

Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com

About Senzime

Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Senzime's employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.

Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world's leading markets. The company's shares are listed on Nasdaq Stockholm Main Market (SEZI). More information is available at senzime.com.

Attachments

Senzime secures contract with top-10 ranked, US East Coast-based university hospital system